Abstract：
UNASSIGNED: Recent development in perioperative treatment of resectable non-small cell lung cancer (NSCLC) have changed the landscape of early lung cancer management. The ADAURA trial has demonstrated the efficacy of adjuvant osimertinib treatment in resectable NSCLC patients; however, studies are required to show which subgroup of patients are at a high risk of relapse and require adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. This study evaluated risk factors for postoperative relapse among patients who underwent complete resection.
UNASSIGNED: Data were obtained from the Korean Association for Lung Cancer Registry (KALC-R), a database created using a retrospective sampling survey by the Korean Central Cancer Registry (KCCR) and the Lung Cancer Registration Committee.
UNASSIGNED: A total of 3,176 patients who underwent curative resection was evaluated. The mean observation time was approximately 35.4 months. Among stage I to IIIA NSCLC patients, the EGFR-mutant subgroup included 867 patients, and 75.2%, 11.2%, and 11.8% were classified as stage I, stage II, and stage III, respectively. Within the EGFR-mutant subgroup, 44 (5.1%) and 121 (14.0%) patients showed early and late recurrence, respectively. Multivariate analysis on association with postoperative relapse among the EGFR-mutant subgroup showed that age, pathologic N and TNM stages, pleural invasion status, and surgery type were independent significant factors.
UNASSIGNED: Among the population that underwent complete resection for early NSCLC with EGFR mutation, patients with advanced stage, pleural invasion, or limited resection are more likely to show postoperative relapse.
UNASSIGNED: Data were obtained from the Korean Association for Lung Cancer Registry (KALC-R), a database created using a retrospective sampling survey by the Korean Central Cancer Registry (KCCR) and the Lung Cancer Registration Committee.
UNASSIGNED: A total of 3,176 patients who underwent curative resection was evaluated. The mean observation time was approximately 35.4 months. Among stage I to IIIA NSCLC patients, the EGFR-mutant subgroup included 867 patients, and 75.2%, 11.2%, and 11.8% were classified as stage I, stage II, and stage III, respectively. Within the EGFR-mutant subgroup, 44 (5.1%) and 121 (14.0%) patients showed early and late recurrence, respectively. Multivariate analysis on association with postoperative relapse among the EGFR-mutant subgroup showed that age, pathologic N and TNM stages, pleural invasion status, and surgery type were independent significant factors.
UNASSIGNED: Among the population that underwent complete resection for early NSCLC with EGFR mutation, patients with advanced stage, pleural invasion, or limited resection are more likely to show postoperative relapse.
摘要：
■可切除的非小细胞肺癌（NSCLC）围手术期治疗的最新进展改变了早期肺癌的治疗前景。ADAURA试验已证明奥希替尼辅助治疗在可切除的NSCLC患者中的疗效；然而，需要研究显示哪些亚组患者的复发风险较高,且需要表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)辅助治疗.这项研究评估了接受完全切除的患者术后复发的危险因素。
■数据来自韩国肺癌登记协会（KALC-R），通过韩国中央癌症登记处(KCCR)和肺癌登记委员会的回顾性抽样调查建立的数据库.
■总共评估了3,176例接受根治性切除术的患者。平均观察时间约为35.4个月。在I至IIIA期NSCLC患者中，EGFR突变亚组包括867例患者，75.2%,11.2%,11.8%被归类为第一阶段，第二阶段,第三阶段,分别。在EGFR突变亚组中，44例（5.1％）和121例（14.0％）患者出现早期和晚期复发，分别。EGFR突变亚组患者的年龄与术后复发相关的多因素分析显示,病理N和TNM分期，胸膜浸润状态，和手术类型是独立的显著影响因素。
■在接受EGFR突变的早期NSCLC完全切除的人群中，晚期患者，胸膜侵犯,或有限的切除更有可能显示术后复发。
■数据来自韩国肺癌登记协会（KALC-R），通过韩国中央癌症登记处(KCCR)和肺癌登记委员会的回顾性抽样调查建立的数据库.
■总共评估了3,176例接受根治性切除术的患者。平均观察时间约为35.4个月。在I至IIIA期NSCLC患者中，EGFR突变亚组包括867例患者，75.2%,11.2%,11.8%被归类为第一阶段，第二阶段,第三阶段,分别。在EGFR突变亚组中，44例（5.1％）和121例（14.0％）患者出现早期和晚期复发，分别。EGFR突变亚组患者的年龄与术后复发相关的多因素分析显示,病理N和TNM分期，胸膜浸润状态，和手术类型是独立的显著影响因素。
■在接受EGFR突变的早期NSCLC完全切除的人群中，晚期患者，胸膜侵犯,或有限的切除更有可能显示术后复发。
